Clinical Trial Detail

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Complete title: APEC1621J (MOLECULAR ANALYSIS FOR THERAPY CHOICE)-PHASE 2

SUBPROTOCOL OF BVD-523FB (ULIXERTINIB) IN PATIENTS WITH TUMORS HARBORING

ACTIVATING MAPK PATHWAY MUTATIONS

Research Study Number	RG1004277
Principal Investigator	Navin Pinto, MD
Phase	II

Look up trial at NIH

Research Study Description

This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a genetic alteration (mutation) in a signaling pathway called MAPK. A signaling pathway consists of a group of molecules in a cell that control one or more cell functions. Genes in the MAPK pathway are frequently mutated in many types of cancers. Ulixertinib may stop the growth of cancer cells that have mutations in the MAPK pathway.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above **

Other eligibility criteria may apply.

Research Study Number	RG1004277
Contact	Advanced Therapeutics Study Line
Telephone	206/987-2553
E-mail

Keywords: Neoplasms, Germ Cell and Embryonal; Neoplasms, Glandular and Epithelial; Sarcoma, Soft Tissue; Nervous System Diseases; Histiocytosis, Langerhans-Cell; Hepatoblastoma

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

RSS feed

Last Modified, June 25, 2019